|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116.58 CHF | +0.45% |
|
+2.50% | +6.39% |
| 01-14 | Dr. Reddy's Laboratories Launches Olopatadine Hydrochloride Ophthalmic Solution in US | MT |
| 01-14 | SciNeuro Grants Novartis Rights for Alzheimer's Disease Drug | MT |
| Capitalization | 279B 239B 223B 207B 387B 25,163B 417B 2,560B 1,007B 12,037B 1,045B 1,024B 44,106B | P/E ratio 2025 * |
20.4x | P/E ratio 2026 * | 20x |
|---|---|---|---|---|---|
| Enterprise value | 300B 257B 239B 223B 416B 27,056B 448B 2,753B 1,083B 12,942B 1,124B 1,101B 47,424B | EV / Sales 2025 * |
5.38x | EV / Sales 2026 * | 5.31x |
| Free-Float |
87.19% | Yield 2025 * |
2.81% | Yield 2026 * | 2.93% |
Last Transcript: Novartis AG
| 1 day | +0.43% | ||
| 1 week | +2.50% | ||
| Current month | +6.39% | ||
| 1 month | +8.73% | ||
| 3 months | +12.07% | ||
| 6 months | +21.38% | ||
| Current year | +6.39% |
| 1 week | 112.48 |  | 116.66 |
| 1 month | 106.78 | | 116.66 |
| Current year | 107.68 | | 116.66 |
| 1 year | 81.1 | | 116.66 |
| 3 years | 73.74 | | 116.66 |
| 5 years | 72.84 | | 116.66 |
| 10 years | 65.09 | | 116.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
| Director of Finance/CFO | 61 | 24/04/2013 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
Liz Doherty
BRD | Director/Board Member | 69 | 01/01/2016 |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 10.4% | 121 M€ | |
| +1.01% | 5.57% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.45% | +2.50% | +28.73% | +35.24% | 279B | |
| -0.36% | -3.14% | +44.08% | +196.80% | 961B | |
| +2.29% | +5.33% | +50.98% | +26.02% | 527B | |
| +0.52% | -4.94% | +26.40% | +44.46% | 392B | |
| +0.67% | +2.06% | +30.27% | +17.58% | 368B | |
| +0.03% | +1.38% | +34.97% | +23.09% | 299B | |
| +2.54% | +2.22% | +11.40% | -1.10% | 276B | |
| -2.33% | +0.51% | -38.47% | -21.85% | 262B | |
| +1.44% | -3.71% | +23.16% | +21.07% | 177B | |
| +1.90% | -0.23% | +36.34% | +43.82% | 154B | |
| Average | +0.60% | +0.35% | +24.79% | +38.51% | 369.46B | |
| Weighted average by Cap. | +0.40% | +0.03% | +30.30% | +67.10% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 55.68B 47.78B 44.48B 41.39B 77.25B 5,026B 83.27B 511B 201B 2,404B 209B 205B 8,810B | 57.1B 49B 45.62B 42.45B 79.22B 5,155B 85.4B 525B 206B 2,466B 214B 210B 9,035B |
| Net income | 14.24B 12.22B 11.38B 10.59B 19.76B 1,286B 21.3B 131B 51.46B 615B 53.41B 52.31B 2,253B | 14.23B 12.21B 11.37B 10.58B 19.74B 1,284B 21.28B 131B 51.42B 614B 53.36B 52.26B 2,251B |
| Net Debt | 20.97B 17.99B 16.75B 15.59B 29.09B 1,893B 31.36B 193B 75.78B 906B 78.64B 77.02B 3,318B | 24.44B 20.97B 19.53B 18.17B 33.91B 2,207B 36.56B 225B 88.33B 1,056B 91.67B 89.78B 3,868B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 116.62 CHF | +0.48% | 247,710 |
| 14/01/26 | 116.06 CHF | +2.13% | 3,785,333 |
| 13/01/26 | 113.64 CHF | -0.18% | 2,229,439 |
| 12/01/26 | 113.84 CHF | -0.18% | 2,047,763 |
| 09/01/26 | 114.04 CHF | +0.25% | 2,164,231 |
Delayed Quote Swiss Exchange, January 15, 2026 at 12:03 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition